secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-06-20T23:59:59+00:00
Accession:  0001171843-25-003985
Event type: debt
Sentiment:  negative
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose enters $8.5M loan agreement with Hanmi for tuspetinib AML development
----------------------------------------------------------------------------

- Loan agreement with Hanmi for up to US$8.5M uncommitted facility to fund continued clinical development of tuspetinib.
- Loan is a related-party transaction; Aptose relies on 'financial hardship' exemption from formal valuation and minority shareholder approval.
- Tuspetinib is an oral agent targeting SYK, FLT3, KIT, JAK1/2, RSK2; ongoing TUSCANY Phase 1/2 trial in newly diagnosed AML with azacitidine and venetoclax.
- Early data from first two dose cohorts showed safety, CRs, and MRD negativity across diverse mutations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325003985/0001171843-25-003985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325003985/f8k_062025.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer